Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
These offers follow the recent agreement with the US Administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026 and today, Novo Nordisk is bringing these prices to consumers months in advance of that commitment
This test maps 14 pathways and identifies genetic predispositions to GLP-1 response, helping personalize your semaglutide or tirzepatide selection before significant out-of-pocket spending occurs
Your BHRC provider will review all options during your consultation
Katranski J, Liang S, Morris D, Suppiah V, Lim CX
Above the 72-hour minimum
US$ 24.77
US$ 20.42
US$ 22.15
US$ 23.34
US$ 23.27
